Skip to content
Methdilazine
Tacaryl (methdilazine) is a small molecule pharmaceutical. Methdilazine was first approved as Tacaryl on 1982-01-01. It is used to treat allergic contact dermatitis, allergic rhinitis perennial, atopic dermatitis, eczema, and pityriasis rosea amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
otorhinolaryngologic diseasesD010038
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
immune system diseasesD007154
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Methdilazine
Tradename
Company
Number
Date
Products
TACARYLWestwood-Squibb PharmaceuticalsN-011950 DISCN1982-01-01
1 products
Hide discontinued
Methdilazine hydrochloride
Tradename
Company
Number
Date
Products
TACARYLWestwood-Squibb PharmaceuticalsN-011950 DISCN1982-01-01
2 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
allergic contact dermatitis—D017449L23
allergic rhinitis perennialEFO_1001417D012221J30.89
atopic dermatitisEFO_0000274D003876L20
eczemaHP_0000964D004485L30.9
pityriasis rosea—D017515L42
urticariaEFO_0005531D014581L50
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
R: Respiratory system drugs
— R06: Antihistamines for systemic use
— R06A: Antihistamines for systemic use
— R06AD: Phenothiazine derivatives, systemic antihistamines
— R06AD04: Methdilazine
HCPCS
No data
Clinical
Clinical Trials
9 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Altitude sicknessD000532EFO_1000782T70.291——2—3
Pulmonary hypertensionD006976EFO_0001361I27.20———1—1
HypoxiaD000860R09.02———1—1
Open-angle glaucomaD005902EFO_0004190H40.1———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
GlaucomaD005901EFO_0000516H40——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Uterine cervical neoplasmsD002583—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMETHDILAZINE
INNmethdilazine
Description
Methdilazine is a phenothiazine substituted on nitrogen by a (1-methylpyrrolidin-3-yl)methyl group; a first-generation antihistamine with anticholinergic properties. It has a role as a histamine antagonist, a cholinergic antagonist and an antipruritic drug. It is a member of phenothiazines and a N-alkylpyrrolidine.
Classification
Small molecule
Drug classvasodilators (undefined group); antiarrhythmic/antianginal/antihypertensive agents, phthalazine like structure
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CN1CCC(CN2c3ccccc3Sc3ccccc32)C1
Identifiers
PDB—
CAS-ID1982-37-2
RxCUI29648
ChEMBL IDCHEMBL1200959
ChEBI ID6823
PubChem CID14677
DrugBankDB00902
UNII ID4Q13LY9Z8X (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 111 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
52 adverse events reported
View more details